MERETEK UBT KIT (W/ PRANACTIN)
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MERETEK UBT KIT (W/ PRANACTIN) (MERETEK UBT KIT (W/ PRANACTIN)).
Meretek UBT Kit contains [13C]urea; Helicobacter pylori urease hydrolyzes [13C]urea to produce [13C]CO2, which is detected in breath to indicate active H. pylori infection.
| Metabolism | Not metabolized; [13C]urea is hydrolyzed by H. pylori urease to [13C]CO2 and ammonia; [13C]CO2 is excreted in breath. |
| Excretion | Urea (13C) is rapidly hydrolyzed by H. pylori urease in the stomach to 13CO2, which is absorbed and exhaled via the lungs; >99% of the 13C dose is eliminated as exhaled 13CO2 within 24 hours. Pranactin (citric acid) is metabolized to CO2 and water; <2% renal elimination. |
| Half-life | Not applicable; 13C is a stable isotope that is rapidly converted to 13CO2; elimination half-life of CO2 from the body is approximately 5-10 minutes under normal respiratory conditions. Clinical context: 13CO2 appearance in breath peaks at 30 minutes post-dose. |
| Protein binding | 13C-urea: negligible (<5%); citric acid: negligible; albumin binding is minimal. |
| Volume of Distribution | 13C-urea distributes throughout total body water; Vd approximately 0.5-0.6 L/kg, reflecting rapid equilibrium with extracellular and intracellular fluid. |
| Bioavailability | Oral: not applicable as a diagnostic agent; ingested 13C-urea is fully available for urease hydrolysis in the stomach; systemic absorption is minimal. |
| Onset of Action | Oral: 13CO2 detection in breath begins within 5-10 minutes, with peak excretion at 30 minutes; clinical detection of H. pylori by breath test is typically measured at 30 minutes post-dose. |
| Duration of Action | Single-dose test; the 13CO2 signal is detectable for up to 6 hours post-dose, but the test is completed within 1 hour; no therapeutic duration. |
75 mg oral pranactin (citric acid) dissolved in 200 mL water, administered once for urea breath test.
| Dosage form | FOR SOLUTION |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Not established; safety and efficacy in pediatric patients have not been studied. |
| Geriatric use | No specific geriatric dose adjustment; use standard adult dose with attention to swallowing ability. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for MERETEK UBT KIT (W/ PRANACTIN) (MERETEK UBT KIT (W/ PRANACTIN)).
| Breastfeeding | No data on excretion in breast milk. Components are minimally absorbed; risk to infant is negligible. Use caution in breastfeeding. M/P ratio not established. |
| Teratogenic Risk | MERETEK UBT KIT contains Pranactin (citric acid, aspartame, and 13C-urea) for urea breath test. No teratogenic effects reported; no fetal risk in any trimester as it is a non-absorbed diagnostic agent. However, aspartame may be contraindicated in phenylketonuria. |
| Fetal Monitoring |
■ FDA Black Box Warning
None.
| Serious Effects |
Known hypersensitivity to [13C]urea or any component of the test meal.
| Precautions | False negatives may occur due to recent use of proton pump inhibitors, bismuth, or antibiotics; false positives may occur with active gastrointestinal bleeding or urease-producing organisms other than H. pylori. |
Loading safety data…
| No specific monitoring required. Standard monitoring for breath test collection. Ensure no phenylketonuria in mother or infant. |
| Fertility Effects | No known effect on fertility. Diagnostic agent with no systemic absorption. |